Cervical Cancer - Pipeline Review, H1 2016

Description: Cervical Cancer - Pipeline Review, H1 2016

Summary


The report provides comprehensive information on the therapeutics under development for Cervical Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cervical Cancer and features dormant and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Cervical Cancer
- The report reviews pipeline therapeutics for Cervical Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Cervical Cancer therapeutics and enlists all their major and minor projects
- The report assesses Cervical Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Cervical Cancer

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Cervical Cancer
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cervical Cancer pipeline depth and
focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Contents:
Introduction
Cervical Cancer Overview
Therapeutics Development
Cervical Cancer - Therapeutics under Development by Companies
Cervical Cancer - Therapeutics under Investigation by Universities/Institutes
Cervical Cancer - Pipeline Products Glance
Cervical Cancer - Products under Development by Companies
Cervical Cancer - Products under Investigation by Universities/Institutes
Cervical Cancer - Companies Involved in Therapeutics Development
Cervical Cancer - Therapeutics Assessment
Drug Profiles
Cervical Cancer - Recent Pipeline Updates
Cervical Cancer - Dormant Projects
Cervical Cancer - Discontinued Products
Cervical Cancer - Product Development Milestones
Appendix
List of Tables
Number of Products under Development for Cervical Cancer, H1 2016
Number of Products under Development for Cervical Cancer - Comparative Analysis, H1 2016
Number of Products under Development by Companies, H1 2016
Number of Products under Development by Companies, H1 2016 (Contd..1)
Number of Products under Development by Companies, H1 2016 (Contd..2)
Number of Products under Development by Companies, H1 2016 (Contd..3)
Number of Products under Development by Companies, H1 2016 (Contd..4)
Number of Products under Investigation by Universities/Institutes, H1 2016
Comparative Analysis by Late Stage Development, H1 2016
Comparative Analysis by Clinical Stage Development, H1 2016
Comparative Analysis by Early Stage Development, H1 2016
Products under Development by Companies, H1 2016
Cervical Cancer - Pipeline by 3SBio Inc., H1 2016
Cervical Cancer - Pipeline by Admedus Ltd, H1 2016
Cervical Cancer - Pipeline by Advaxis, Inc., H1 2016
Cervical Cancer - Pipeline by AdvanCence Laboratories, LLC, H1 2016
Cervical Cancer - Pipeline by AnGes MG, Inc., H1 2016
Cervical Cancer - Pipeline by Antigen Express, Inc., H1 2016
Cervical Cancer - Pipeline by Arbor Vita Corporation, H1 2016
Cervical Cancer - Pipeline by ArQule, Inc., H1 2016
Cervical Cancer - Pipeline by AstraZeneca Plc, H1 2016
Cervical Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H1 2016
Cervical Cancer - Pipeline by Azaya Therapeutics, Inc., H1 2016
Cervical Cancer - Pipeline by Blirt S.A., H1 2016
Cervical Cancer - Pipeline by Bristol-Myers Squibb Company, H1 2016
Cervical Cancer - Pipeline by Cancer Research Technology Limited, H1 2016
Cervical Cancer - Pipeline by Cellceutix Corporation, H1 2016
Cervical Cancer - Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2016
Cervical Cancer - Pipeline by Coherus BioSciences, Inc., H1 2016
Cervical Cancer - Pipeline by Critical Outcome Technologies Inc., H1 2016
Cervical Cancer - Pipeline by CZ BioMed Corp, H1 2016
Cervical Cancer - Pipeline by DelMar Pharmaceuticals, Inc., H1 2016
Cervical Cancer - Pipeline by Dr. Reddy's Laboratories Limited, H1 2016
Cervical Cancer - Pipeline by EirGenix Inc., H1 2016
Cervical Cancer - Pipeline by Eisai Co., Ltd., H1 2016
Cervical Cancer - Pipeline by Eureka Therapeutics, Inc., H1 2016
Cervical Cancer - Pipeline by EyeGene, Inc., H1 2016
Cervical Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016
Cervical Cancer - Pipeline by Formune S.L., H1 2016
Cervical Cancer - Pipeline by Genexine, Inc., H1 2016
Cervical Cancer - Pipeline by Genmab A/S, H1 2016
Cervical Cancer - Pipeline by Genor BioPharma Co., Ltd., H1 2016
Cervical Cancer - Pipeline by Genticel S.A., H1 2016
Cervical Cancer - Pipeline by GlaxoSmithKline Plc, H1 2016
Cervical Cancer - Pipeline by Immunovaccine, Inc., H1 2016
Cervical Cancer - Pipeline by ISA Pharmaceuticals B.V., H1 2016
Cervical Cancer - Pipeline by Johnson & Johnson, H1 2016
Cervical Cancer - Pipeline by Karyopharm Therapeutics, Inc., H1 2016
Cervical Cancer - Pipeline by Kite Pharma, Inc., H1 2016
Cervical Cancer - Pipeline by LondonPharma Ltd, H1 2016
Cervical Cancer - Pipeline by Mabion SA, H1 2016
Cervical Cancer - Pipeline by MedImmune, LLC, H1 2016
Cervical Cancer - Pipeline by MEI Pharma, Inc., H1 2016
Cervical Cancer - Pipeline by Mundipharma International Ltd, H1 2016
Cervical Cancer - Pipeline by Mycenax Biotech Inc., H1 2016
Cervical Cancer - Pipeline by Nanotherapeutics, Inc., H1 2016
Cervical Cancer - Pipeline by Nektar Therapeutics, H1 2016
Cervical Cancer - Pipeline by Novartis AG, H1 2016
Cervical Cancer - Pipeline by Oncobiologics, Inc., H1 2016
Cervical Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016
Cervical Cancer - Pipeline by Oryx GmbH & Co. KG, H1 2016
Cervical Cancer - Pipeline by Otsuka Holdings Co., Ltd., H1 2016
Cervical Cancer - Pipeline by PDS Biotechnology Corporation, H1 2016
Cervical Cancer - Pipeline by Pfizer Inc., H1 2016
Cervical Cancer - Pipeline by Psicofarma S.A. de C.V., H1 2016
Cervical Cancer - Pipeline by Rexahn Pharmaceuticals, Inc., H1 2016
Cervical Cancer - Pipeline by Samyang Holdings Corporation, H1 2016
Cervical Cancer - Pipeline by Sanofi, H1 2016
Comparative Analysis by Late Stage Development, H1 2016
Comparative Analysis by Clinical Stage Development, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Assessment by Monotherapy Products, H1 2016
Assessment by Combination Products, H1 2016
Number of Products by Top 10 Targets, H1 2016
Number of Products by Stage and Top 10 Targets, H1 2016
Number of Products by Top 10 Mechanism of Actions, H1 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
Number of Products by Top 10 Routes of Administration, H1 2016
Number of Products by Stage and Top 10 Routes of Administration, H1 2016
Number of Products by Top 10 Molecule Types, H1 2016
Number of Products by Stage and Top 10 Molecule Types, H1 2016

Ordering:
Order Online - [http://www.researchandmarkets.com/reports/3759022/](http://www.researchandmarkets.com/reports/3759022/)
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

- Product Name: Cervical Cancer - Pipeline Review, H1 2016
- Web Address: http://www.researchandmarkets.com/reports/3759022/
- Office Code: SCH3G82Z

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>USD 2000</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td></td>
</tr>
<tr>
<td>Electronic (PDF) - Site License:</td>
<td>USD 4000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide:</td>
<td>USD 6000</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

- Title: □ Mr □ Mrs □ Dr □ Miss □ Ms □ Prof □
- First Name: ____________________________  Last Name: ____________________________
- Email Address: *
- Job Title: ________________________________
- Organisation: ____________________________
- Address: ________________________________
- City: ________________________________
- Postal / Zip Code: ________________________________
- Country: ________________________________
- Phone Number: ________________________________
- Fax Number: ________________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB985330833103083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: 

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World